Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06936189

Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)(Extended Follow-Up)

Purpose: To assess the long-term safety and efficacy of the intravascular lithotripsy system for pre-treatment of calcified carotid artery stenosis.

Design: Prospective, multicenter, single-arm study with an extended follow-up period.

Sample Size: 204 participants (based on the final number of cases enrolled in the registration trial).

Endpoints:

Primary: Surgical success rate (residual stenosis <30% after stenting). Secondary: Target lesion re-narrowing rate, target lesion revascularization rate, MAE rate, ipsilateral stroke rate, and MACCE rate at 3 and 6 months postoperatively.

Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively.

Inclusion criteria:

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Ethics and Consent: The trial will be conducted in accordance with the Helsinki Declaration and Chinese regulations. Informed consent will be obtained from all participants or their legal guardians.

Sponsor: Shanghai Lanfan Boyuan Medical Technology Co., Ltd. Principal Investigator: Professor Huo Xiaochuan, Beijing Anzhen Hospital.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

### Detailed Description

This clinical trial evaluates the safety and long-term efficacy of a disposable neurovascular intravascular lithotripsy (IVL) catheter and intravascular lithotripsy treatment device for pre-treatment of calcified lesions in the extracranial segment of the carotid artery. The study is designed as a prospective, multicenter, single-arm trial (extended follow-up period).

#### Study Population:

All patients participating in this extended follow-up period are sourced from the registered clinical trial.(The registered clinical trial:Participants aged 18-80 years with symptomatic (≥50%) or asymptomatic (≥70%) calcified carotid artery stenosis confirmed by CT angiography (CTA) and digital subtraction angiography (DSA) are eligible. Patients who have failed conventional balloon dilation and are planned for carotid artery stenting (CAS) will be included.)

#### Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively. Assessments will include clinical evaluations, imaging studies (CT angiography or carotid ultrasound), and recording of adverse events.

  • Endpoints:
  • **Primary Endpoint**: Surgical success rate defined as residual stenosis <30% after stenting.
  • **Secondary Endpoints**: Target lesion re-narrowing rate, target lesion revascularization rate, MAE (major adverse events) rate, ipsilateral stroke rate, and MACCE (major adverse cardiovascular and cerebrovascular events) rate at 3 and 6 months postoperatively.
  • Ethical Considerations:

Informed consent will be obtained from all participants or their legal guardians. The study will be conducted in accordance with the Helsinki Declaration and local regulatory requirements.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Exclusion criteria

none

Treatment and study plan

Primary outcomes

  1. Target lesion re-narrowing rate

    Time frame: at 3 months and 6 months postoperatively

    Proportion of patients with ≥50% diameter stenosis at the target lesion, assessed by imaging at 3 and 6 months.

Secondary outcomes

  1. Target lesion revascularization rate

    Time frame: at 3 months and 6 months postoperatively

    Incidence of repeat revascularization procedures at the treated lesion, evaluated at 3 and 6 months.

  2. MAE (Major Adverse Events) rate

    Time frame: at 3 months and 6 months postoperatively

    Rate of major adverse events (death, myocardial infarction, stroke) within 3 and 6 months.

  3. Ipsilateral stroke rate

    Time frame: at 3 months and 6 months postoperatively

    Incidence of stroke on the treated side, confirmed by clinical and imaging studies at 3 and 6 months.

  4. MACCE (Major Adverse Cardio-Cerebrovascular Events) rate

    Time frame: at 3 months and 6 months postoperatively

    Composite rate of death, stroke, myocardial infarction, and revascularization at 3 and 6 months.

Study contacts

Contact information is provided by the study sponsor or research team.

Xiaochuan Huo

CONTACT

[email protected]

010-64412431

Sponsors and collaborators

Lead sponsor

Shanghai Bluesail Boyuan Medical Technology Co., Ltd.

Industry

Registry information

Official study title

A Prospective, Multicenter, Single-Arm Objective Performance Criteria Clinical Trial Evaluating the Safety and Efficacy of a Single-Use Neurovascular Intravascular Shockwave Catheter and Intravascular Shockwave Therapy Device for Pretreatment of Calcified Lesions in the Extracranial Carotid Artery (CREATE Trial)) (Extended Follow-Up)

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Apr 20, 2025
Registry last updated
May 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.